A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia.

Trial Profile

A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Paliperidone; Risperidone
  • Indications Schizophrenia
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 22 Jul 2011 Results published in the International Journal of Neuropsychopharmacology.
    • 18 May 2009 Results presented at the 162nd Annual Meeting of the American Psychiatric Association (APA 2009).
    • 10 Dec 2008 Primary endpoint 'Positive and Negative Syndrome Scale' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top